The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer has decided to halt the development of its potential once-daily pill treatment for obesity due to safety concerns ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Experts say the tariffs are unlikely to bring back production of generic medicines, given their slim profit margins ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the most ...

Pfizer stopped developing danuglipron, a daily oral obesity drug, due to a patient's potential liver injury during the trial.

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...